Safety of a fixed-dose combination of artesunate and amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in real-life conditions of use in Côte d’Ivoire

Table 3 Potentially ASAQ-related adverse events

	Number of adverse events	Number of episodes	Incidence^a
Any potentially ASAQ-related adverse event	929	837	5.5%
Asthenia	410	410	2.7
Somnolence	134	134	0.9
Vomiting	89	89	0.6
Dizziness	84	84	0.6
Diarrhoea	21	21	0.1
Insomnia	13	13	0.1
Abdominal pain	12	12	0.1
Pruritus	26	26	0.2
Decreased appetite	28	28	0.2
Cough	13	13	0.1

Only individual adverse events reported during more than ten malaria episodes are listed in this table
^aCalculated with respect to the 15,228 documented malaria episodes

ISSN: 1475-2875